CARE-CP (Teste de avaliação rápida ambulatorial cardiovascular para pacientes com dor torácica) (CARE-CP)
CARE-CP (Teste de Avaliação Ambulatorial Cardiovascular Rápida para Pacientes com Dor Torácica)
The goal of this study is to determine if rapid outpatient evaluation vs hospitalization management is the best strategy (based on patient-centered measures and safe, equitable, and efficient resource use) for evaluating patients with acute chest pain who are at moderate risk for acute coronary syndrome (ACS). Patients will be randomized in the Emergency Department to either an outpatient evaluation (CARE-CP) or hospitalization evaluation for their symptoms.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
Current care patterns for the 7 million patients visiting Emergency Departments (EDs) in the United States with chest pain are heterogeneous and not sustainable from a healthcare quality or economic perspective. Chest pain is the second most common cause of ED visits and the most common reason for short-stay hospitalizations. During these hospitalizations patients undergo in-depth evaluations (stress testing, computed tomography coronary angiography, or invasive angiography), but ultimately <10% are diagnosed with acute coronary syndrome (ACS). These evaluations cost $3 billion annually and strain health system resources without clear evidence of improved health outcomes or patient experience. The preliminary data suggest that moderate risk patients (35% of patients with chest pain) can be safely managed as outpatients using a cardiovascular ambulatory rapid evaluation (CARE-CP) strategy as an alternative to hospitalization. In the CARE-CP strategy, patients are discharged from the ED and receive outpatient clinic follow-up within 72 hours focused on medical management for cardiovascular risk factors (e.g., hypertension, diabetes) and determining whether further cardiac testing is needed. This strategy aims to enhance patient-centered outcomes while safely and equitably decreasing hospital resource utilization. However, equipoise exists between outpatient and hospitalization strategies for moderate risk patients. There is a paucity of prospective data evaluating the efficacy and patient-centeredness of outpatient chest pain evaluation strategies in moderate risk patients. Thus, it is unclear whether use of an outpatient chest pain management strategy (CARE-CP) will safely reduce healthcare utilization and be preferred by patients compared to a traditional hospitalization strategy. To address this key evidence gap, the study proposes the first prospective multisite randomized trial testing outpatient vs hospitalization strategies in moderate risk patients. The research teams will randomize 502 patients 1:1 to the CARE-CP or hospitalization management arms at three ED sites with a history of high recruitment rates and productive collaborations in cardiovascular clinical trials. The primary outcome will be hospital-free days (HFD) over a 30-day period. This novel trial addresses a key evidence gap by providing guidance on how best to evaluate moderate risk ED patients with acute chest pain. Without this guidance care patterns are likely to remain heterogeneous, inefficient, non-patient-centered, and unguided by the highest level of evidence. We hypothesize that data from this trial will support widespread implementation of a CARE-CP strategy, which could improve the quality and value of care for millions of patients in the U.S. and beyond.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Lauren Koehler
- Número de telefone: 336-716-4646
- E-mail: Lauren.Koehler@Advocatehealth.org
Locais de estudo
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28203
- Recrutamento
- Carolinas Medical Center
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Recrutamento
- Wake Forest University Health Sciences
-
Contato:
- Lauren Koehler
- E-mail: Lauren.Koehler@Advocatehealth.org
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Age ≥21 years old
-
Chest pain or Symptoms of acute coronary syndrome (ACS)
-
Moderate risk of ACS (all of the below)
-
Hear Score 4-6
-
Non-Ischemic electrocardiogram (ECG)
-
Two Troponin measures < Sex-Specific Upper Reference Limit
- Women <15 pg/ml
- Men <20 pg/ml
-
No prior coronary artery disease (CAD)
- No Prior Myocardial Infarction (MI)
- No Prior Coronary Revascularization Procedures
- No Patients with ≥ 70% Obstructive Coronary Disease
Exclusion Criteria:
- ST Elevation Myocardial Infarction (STEMI) Activation
- ST Changes or new T-wave inversions ≥1mm on ECG
- Any Elevated Troponin Measure (Based on Sex-Specific 99th Percentile)
- Serial change between Troponin Measures (Delta) ≥5 pg/mL
- Stress Echocardiography, Nuclear Stress Test, Stress ECG, Stress Cardiac MRI, Coronary CT Angiogram (CCTA), Invasive Coronary Angiography (Cardiac Cath) within 1 year
- "Clean" CCTA or Cardiac Cath (0% stenosis in all vessels) within the past 2 years
- Chest Trauma
- Pregnancy
- Life Expectancy < 1 year
- Other comorbid conditions requiring hospitalization
- Unstable Vitals (Blood Pressure <90, Heart Rate >120 or <50, O2 Sat <90%)
- End Stage Renal Disease; Dialysis or estimated glomerular filtration rate (eGFR) <30 mL/min
- Transfers From Another Hospital
- Non-English Speaking
- Prisoners
- Prior Enrollment
- Already Enrolled in Other Interventional Trial
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Outro: Outpatient Evaluation
Patients randomized to this arm are discharged and receive outpatient evaluation, or cardiovascular ambulatory rapid evaluation (CARE), focused on medical management for cardiovascular risk factors (e.g. hypertension) within 72 hours of Emergency Department discharge. |
Subjects will receive an outpatient evaluation within 72 of being discharged from the ED.
Outros nomes:
|
|
Outro: Hospitalization Evaluation
Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding. |
Patients randomized to this arm receive evaluation for their symptoms in a hospital ward, observation unit, or emergency department boarding. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hospital-free days (HFD) at 30-days post-randomization
Prazo: Day 30
|
Time spent in a hospital setting at 30 days post-randomization will be measured and subtracted from time spent outside the hospital. Hospital time is broadly defined, based on a patient-centered definition of cumulative time spent in the ED, observation unit, or hospital ward. Consistent with prior trials, patients who experience death during the follow-up period are assigned zero HFDs. |
Day 30
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Hospital-free days (HFD) at 1-year post-randomization
Prazo: Year 1
|
Time spent in a hospital setting at 1 year post-randomization will be measured and subtracted from time spent outside the hospital. Hospital time is broadly defined, based on a patient-centered definition of cumulative time spent in the ED, observation unit, or hospital ward. Consistent with prior trials, patients who experience death during the follow-up period are assigned zero HFDs. |
Year 1
|
|
Cardiovascular Hospital-free days (HFD) at 30-days post-randomization
Prazo: Day 30
|
Rates of cardiovascular rehospitalizations at 30-days post-randomization will be analyzed between the two treatment arms. |
Day 30
|
|
Cardiovascular Hospital-free days (HFD) at 1 year post-randomization
Prazo: Year 1
|
Rates of cardiovascular rehospitalizations at 1 year post-randomization will be analyzed between the two treatment arms. |
Year 1
|
|
Rate of noninvasive cardiac testing at 30-days post-randomization
Prazo: Day 30
|
The rates of noninvasive testing (stress testing and coronary computed tomography angiography), at 30-days post-randomization will be analyzed between the two treatment arms. |
Day 30
|
|
Rate of noninvasive cardiac testing at 1 year post-randomization
Prazo: Year 1
|
The rates of noninvasive testing (stress testing and coronary computed tomography angiography), at 1 year post-randomization will be analyzed between the two treatment arms. |
Year 1
|
|
Rate of invasive cardiac testing at 30-days post-randomization
Prazo: Day 30
|
The rates of invasive testing (coronary angiography), at 30-days post-randomization will be analyzed between the two treatment arms. |
Day 30
|
|
Rate of invasive cardiac testing at 1 year post-randomization
Prazo: Year 1
|
The rates of invasive testing (coronary angiography), at 1 year post-randomization will be analyzed between the two treatment arms. |
Year 1
|
|
Cardiovascular repeat ED visits at 30-days post-randomization
Prazo: Day 30
|
The rates of Cardiovascular repeat ED visits at 30-days post-randomization will be analyzed between the two treatment arms.The ED visit will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Day 30
|
|
Cardiovascular repeat ED visits at 1 year post-randomization
Prazo: Year 1
|
The rates of Cardiovascular repeat ED visits at 1 year post-randomization will be analyzed between the two treatment arms.The ED visit will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Year 1
|
|
Cardiovascular rehospitalizations at 30-days post-randomization
Prazo: Day 30
|
The rates of Cardiovascular rehospitalizations at 30-days post-randomization will be analyzed between the two treatment arms.The rehospitalization will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Day 30
|
|
Cardiovascular rehospitalizations at 1 year post-randomization
Prazo: Year 1
|
The rates of Cardiovascular rehospitalizations at 1 year post-randomization will be analyzed between the two treatment arms.The rehospitalization will be categorized as cardiovascular if a cardiac procedure is performed, the primary reason for admission is possible ACS, or a discharge diagnosis relates to chest pain, MI, ACS, heart failure, or other cardiac disease (e.g., dysrhythmia, pericardial disease, etc.). Cardiac procedures include stress testing, noninvasive and invasive coronary angiography, coronary revascularization, and pacemaker or defibrillator insertion. |
Year 1
|
|
Patient satisfaction (SAPS questionnaire)
Prazo: Day 30
|
Satisfaction will be assessed using the Short Assessment of Patient Satisfaction (SAPS). A patient satisfaction survey will be sent that evaluates clinician communication, participation in medical decision-making, respect by the clinician, clinician carefulness, time with the clinician, and treatment effect, in any service setting on a five-point Likert scale from "very dissatisfied" to "very satisfied". Scores from each item are summed and range from 0 (extremely dissatisfied) to 28 (extremely satisfied). |
Day 30
|
|
Patient experience (GS-PEQ instrument)
Prazo: Day 30
|
Experience will be measured using the Generic Short Patient Experience Questionnaire (GS-PEQ). A patient experience survey will also be sent out to evaluate which assesses timeliness and organization of medical services, confidence in the clinician and treatment, patient involvement in decision-making, clinician communication, patient outcomes, and incorrect treatment on a 5-point Likert-scale from "not at all" to "to a very large extent" and one question (on wait times) scored on a 4-point Likert scale from "no" to "yes, way too long. A mean score can be calculated for each patient, with higher scores indicating better experience. |
Day 30
|
|
Out-of-pocket cost (based on billing data)
Prazo: Day 30
|
Patient satisfaction, patient experience, and out-of-pocket costs will be measured in all trial participants. Financial records will be utilized from each site to determine patient billing, including the amount covered by insurance vs. patient responsibility. Each item will be measured in U.S. dollars and summed for total cost. |
Day 30
|
|
Drivers of Patient Satisfaction and Experience (Qualitative)
Prazo: Day 30
|
A subset of 100 patients (50 from each arm) will be purposively selected to ensure diversity in sex, race, ethnicity, socioeconomic status (SES), and health literacy for 30-minute semi-structured phone interviews to determine key drivers of patient satisfaction and experience. We will use an explanatory sequential mixed-methods design, in which participants' quantitative data will guide the collection and analysis of their qualitative data.These data will provide key context and meaning to the patient's quantitative response regarding patient satisfaction, experience, and out-of-pocket cost. |
Day 30
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Simon Mahler, MD, MS, Wake Forest University Health Sciences
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- IRB00092604
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .